#MIPS 2022 Reporting

[outsourcemedical]

[qppmips]

2022 QPP MIPS Reporting Attestation is in Full Swing!

The MIPS 2022 Performance Year MIPS Reporting Period deadline is around the corner. Let’s now get to know about it in detail and be more focused on MIPS 2022 attestation. Qpp MIPS 2022 Performance Year (PY) has gone through so many deadlines. One of those deadlines hasn’t come yet, though MIPS 2022 Performance Year reporting attestation deadline is March 31, 2023. If you need any help with attestation or even with assistance throughout the year to improve your scores. QPP MIPS experts are here to do so. For now, let’s just focus on MIPS 2022 attestation.

Read more:https://mircarie.com/2022-qpp-mips-reporting-attestation-is-in-full-swing/

Phone number: (888) 902-1035

Address: Ontario, California, Ontario, CA 91761, USA

Website:https://qppmips.com/

[mipsreporting]

CMS recently released Proposed Rule for the MIPS 2022 performance period. The window for commenting is officially closed. However, we could get an idea of what the next year will hold for the eligible clinicians. Here are key takeaways.

[creativemains]

Aruna chakrala

ARUNA CHAKRALA FULL

ARUNA CHAKRALA REGISTRATION

Yes "What does it mean "accepts medicare assignment"? Providers must enroll in PECOS to avoid denied claims. A NPI number is necessary to register in PECOS. PECOS is Medicare's enrollment and revalidation system and it is the primary source of information about verified Medicare professionals. PECOS is the Medicare Provider, Enrollment, Chain and Ownership System. PECOS Enrollment and Medicare Participation The purpose of this information is to help people with Medicare make informed decisions and incentivize doctors and clinicians to maximize performance. The provider participated in Medicare's Quality Payment Program under the Merit-based Incentive Payment System (MIPS) and has an overall final score of 96.1, based on four performance areas: quality, improvement activities, promoting interoperability, and cost. Medicare beneficiaries still have to pay a coinsurance or copayment amount for a visit or service. Participating providers may not charge Medicare beneficiaries more than Medicare's approved amount for their services.

ARUNA CHAKRALA FULL

The provider is eligible to order or refer: Part B Clinical Laboratory and Imaging, Durable Medical Equipment (DME), a Home Health Agency (HHA) and Power Mobility Devices.Īruna Chakrala is registered with Medicare and accepts claims assignment, this means the provider accepts Medicare's approved amount for the cost of rendered services as full payment. An internist typically monitors chronic physical conditions, identifies acute diseases, provides family planning, provides counseling about wellness and disease prevention, etc.Aruna Chakrala is enrolled in PECOS and is eligible to order or refer health care services for Medicare patients. Internists are trained to care for adults of all ages for many different medical conditions. Aruna Chakrala M.d.,pc is a physician who has completed an internal medicine residency and is board-certified or board-eligible in an internist specialty. You will Get Updated Information in Next 2 Hour by visiting again.666 PLAINSBORO RD SUITE 1020 PLAINSBORO, NJ 08536Īn internist like Dr. If you still notice any discrepancy in Company Information, please help by reporting it to us. If you feel the information is not up-to-date, you may request to get this page auto-updated now. The information shown is as on Jun 25, 2022. For any Query You can reach this company by email address or Postal address.ĬHAKRALA ENTERPRISES PRIVATE LIMITED's Annual General Meeting (AGM) was last held on and as per records from Ministry of Corporate Affairs (MCA), its balance sheet was last filed on Jan 01, 1900.ĭirectors of CHAKRALA ENTERPRISES PRIVATE LIMITED areĬurrent status of CHAKRALA ENTERPRISES PRIVATE LIMITED is - ACTIVE. Its Email address is and its registered address is where Company is actual registered : D.No.14-2-1894, 14th Cross RoadPlot No.830, Magunta Layout Nellore, INDIA, 524003.

ARUNA CHAKRALA REGISTRATION

100000.Īs Per Registration of Company, It involves under in Business Activity Class / Subclass Code 92412, Main Activity of the said Company CHAKRALA ENTERPRISES PRIVATE LIMITED is :, Activities of sports and game schools, including specialised sports training centres, It Comes Under Division RECREATIONAL, CULTURAL AND SPORTING ACTIVITIES and this come under scetion OTHER COMMUNITY, SOCIAL AND PERSONAL SERVICE ACTIVITIES.ĬHAKRALA ENTERPRISES PRIVATE LIMITED Corporate Identification Number is U92412AP2011PTC074797 and its registration number is 074797. As regarding the financial status on the time of registration of CHAKRALA ENTERPRISES PRIVATE LIMITED Company its authorized share capital is Rs. CHAKRALA ENTERPRISES PRIVATE LIMITED is classified as Non-govt company and is registered at Registrar of Companies located in ROC-VIJAYAWADA. CHAKRALA ENTERPRISES PRIVATE LIMITED is a Private Company, who was incorporated 11 Year(s) 3 Month(s) 2 Day(s) ago on dated 0.

[brookemilosek]

Get their attention-and keep it that way!

3 Strategies to Grab your Audience by the Horns:

Do you have your audience’s attention? Grabbing their attention is the first step towards success in social media. This can be challenging for several reasons. Research confirms that users on social media tend to exercise a very short attention span, and it is essential to grab their attention within the first ten seconds. Another challenge occurs due to the rise in users. According to Close Scheinbaum (2017) over one fifth of Americans report constant use online. Also, reports by Aliverdi, Farajidana, and Tourzani (2022) expand on this saying that 521 million new users have joined social media by 2021. Now, there are strategies you can implement to greatly increase your chances of gaining attention from your desired (or undesired) audiences. First, it is important to remember that emotional and moral content tends to gain attention. Brady, Gantman, and Van Bavel (2020) explain that these types of content are related to goal attainment and are prioritized in early visual attention. Another strategy you may want to try is to be a bit controversial. This may sound like a bad idea but it is important to let your audience know how you feel and where you stand- many may relate! Horn (2017) explains that you should not be afraid to say how you feel because many people can relate and will appreciate the honesty. Lastly, SPEAK UP! You can’t grab a viewers attention if they cant hear or understand what you are saying.

Once You Have Their Attention-Keep it That Way!

Is your audience staying engaged? Once you have the attention of your viewers, your work is not done! It is important to understand that your audience must stay engaged to ensure that your conveying the information desired and keeping them interested and coming back for more. Tsimonis and Dimitriadis  (2014) describe some types of engagement that many platforms offer such as collaborating on content, sharing insights, and connecting for business. There are some steps you can take to increase your engagement and influence with your audience. First, it is important to respond to users comments in a rapid and professional manner. Even if you aren’t on a business venture you should still be responding to your commenters to increase your engagement. Responding to comments related to your business or services have the potential of boosting your reputation and sales. Next, a strategy shared by Horn (2017) explains that you can use common concerns from your audience and create a “frequent questions” section within your platform or website. Lastly, follow-up is important as well. It is crucial that not only should you respond to your audience but if you feel that they could use some extra insight or help with an issue it is always important to follow up with them, showing you can and appreciate the time they have given to you as well.

Hopefully you can implement some of the strategies mentioned to boost your content and confidence on social media!

References:

Aliverdi, F., Farajidana, H., & Tourzani, Z.M. (2022, July 5). Social networks and internet emotional relationships on mental health and quality of life in students: structural equation modeling. 

Brady, W. J., Gantman, A. P., & Van Batel, J. J. (2020). Attentional capture helps explain why moral and emotional content go viral. Journal of Experimental Psychology: General, 149(4), 746-756. https://doi.org/10.1037/xge0000673.supp (supplemental)

Brian Horn. (2017, July 20). 7 ways to get attention on social media. https://marketinginsiders.com/get-attention-on-social-media/

Close Scheinbaum, A. (Ed.). (2017). The dark side of social media: A consumer psychology perspective. Routledge.

Tsimonis, G., & Dimitriadis, S. (2014). Brand strategies in social media. Marketing Intelligence & Planning, 32(3), 328-344. https://doi.org/10.1108/MIP-04-2013-0056

[neomdincblog]

“NEO MD MIPS 2022”

NEO MD is the 2022 CMS Certified Registry that provides submission and consultancy services to all specializations. NEO MD consultant will finalize the outline of the program within one week. This will include the below steps: Step 1: Decision on how to report: EHR, Claim or Registry or a combination of manual data entry into Registry and Claim based reporting. Step 2: Review the measure options currently available. Take note on which of the outcome or high priority measures you can most expeditiously report. Step 3: Determine whether the physician will be avoiding the penalty or go for a possible bonus and the size of bonus you would like to obtain. That is also dependent upon the time in which the physician signs up. NEO MD will work across all category: a. Data Analysis. b. Measure selection. c. Selection of reporting option. d. Selection of reporting mechanism. e. Submission of data to CMS certified registry For more details, please call at (929) 502-3636 or email at registry@neomdinc.com

[renubresearchanalysis]

Global Lung Cancer Diagnostics Market to Reach USD 3.6 Billion by 2027

According to Renub Research report titled “Lung Cancer Diagnostics Market, Size, Share, Global Forecast 2022-2027, Industry Trends, Impact of COVID-19, Opportunity Company Analysis” the Lung Cancer Diagnostics Market Size was USD 2.3 Billion in 2021. Lung cancer is the most typical cause of cancer-related mortality across the world. Smoking stays the predominant risk factor for lung cancer. Lung cancers are categorized histological into small and non–small cell lung cancers. The most common manifestation of lung cancer is dyspnea, cough, hemoptysis, and systemic symptoms such as weight loss and anorexia. These categories are used for treatment decisions and confining prognosis. The diagnostic evaluation of patients with presumed lung cancer includes tissue diagnosis; a complete staging work-up, including evaluation of metastases; and a functional patient evaluation.

Some Key Trends in the Lung Cancer Diagnostics Market:

As per WHO (World Health Organisation), in 2020, lungs cancer is the most frequently diagnosed (11.6% of all cases), followed by female breast (11.6%) and colorectal cancers (10.2%).

Globally, the adoption of advanced multimodal diagnostic approaches heavily influences lung cancer diagnosis. For instance, liquid biopsy and breath analysis developments are the most promising and advanced technologies for detecting biomarkers associated with lung cancer.

AI and Wearable devices are two niche areas that require development and standardization for commercialization. The upcoming technology based on nano-systems includes robots, fibers, and particles for sensitive detection of lung cancer.

Soon, nanotechnology-based theranostics, aptamers, and MIPs will occur in the early-stage diagnosis of lung cancer. These trends boost the demand for lung cancer diagnostics attributed to their laid-back usage and comparatively reduced cost.

For Lung Cancer Diagnosis Imaging Tests are the Primary Screening Techniques

Over the years, test types such as Imaging Test, Biopsy, Sputum Cytology, Molecular Test, and Others have become suitably placed diagnostic in lung cancer. The imaging tests segment was recognized as the most significant test segment due to the high usage rates of various imaging techniques, including CT scan MRI and X-ray, as the primary screening techniques used for lung cancer diagnosis. Imaging tests perform as the initial screening tool for lung cancer diagnosis and are helpful throughout the treatment period. Further, molecular tests about lung cancer facilitate personalized treatments. These tests are utilized to identify genes, specific proteins,  and other tumor-specific factors known as mutations, including ALK, EGFR, BRAF,  ROS1, HER2, and RET.

Request a Free Sample Copy of the Report: https://www.renub.com/request-sample-page.php?gturl=lung-cancer-diagnostics-market-p.php

Worldwide Lung Cancer Diagnostics Industry will grow with a CAGR of 7.75% from 2021-2027

Besides, the lung cancer diagnostic market is segmented into Small-cell Lung Cancer Diagnostics and Non-Small-cell Lung Cancer Diagnostics. Small cell lung cancer spreads quickly in the body, making detecting this cancer at an early-stage difficult. However, people with non-small cell lung cancer can be treated with surgery, chemotherapy, radiation therapy, targeted therapy, or a combination of these treatments. Various subtypes of NSCLC include Adenocarcinoma, Squamous Cell Carcinoma, Large cell carcinoma, and other less frequent NSCLCs.

Along with this, Hospitals & Clinics, Diagnostic Centers, and Research institutes remain the most lucrative end-users of lung cancer diagnostics in the global market. There is a massive demand for lung cancer diagnostic in hospitals & clinics due to the rising number of patients visiting hospitals, the increasing number of in-house diagnostic procedures performed in hospitals, and cumulative awareness regarding early diagnosis.

Worldwide Rising Prevalence of Lungs Cancer in 2021:

As per the American Cancer Society’s for lung cancer in the United States, 235,760 new cases of lung cancer (116,660 in women and 119,100 in men) and 131,880 deaths from lung cancer (62,470 in women and 69,410 in men)

As per Japanese times, 130,000 people in Japan contract lung cancer every year.

According to LuCE, more than 310,000 adults all over Europe were diagnosed with lung cancer.

COVID-19 Impact:

With the outbreak of the COVID-19, the lung cancer diagnostic market has had a significant setback in terms of growth. As the COVID-19 cases grew, the healthcare system turned its focus in curbing the disease, resulting in the delay of diagnosis and treatment of other chronic conditions like cancer. Thus, the pandemic scenario harms the lung cancer diagnostics industry.

Follow the link for the full report with detailed TOC and list of figures and tables: https://www.renub.com/lung-cancer-diagnostics-market-p.php

Competitive Landscape:

Prominent players such as Illumina, Inc., Abbott Laboratories, Thermo Fisher Scientific, Inc, QIAGEN N.V., and Roche Holding AG embrace innovative approaches such as ground-breaking marketing tactics and technological advances for cancer screening mergers and acquisitions.

Market Summary:

Diagnosis Test Type – Our Report covered by Diagnosis Test Type in the 5 viewpoints (Imaging Test, Biopsy, Sputum Cytology, Molecular Test and Others)

Lung Cancer Type – Renub Research Report covers by Lung Cancer Type in the 2 viewpoints (Small-cell Lung Cancer Diagnostics and Non-Small-cell Lung Cancer Diagnostics)

Non-Small- cell Lung Cancer Diagnostics – This Report covers by Non-Small-cell Lung Cancer Diagnostics into 4 viewpoints (Adenocarcinoma, Squamous Cell Carcinoma, Large cell carcinoma and others and not otherwise specified)

End-User – We have covered Global Lung Cancer Diagnostics Market by End-User in the 4 viewpoints (Hospitals & Clinics, Diagnostic Centers, Research Institute and Others)

Region- This Report covers Global Lung Cancer Diagnostics Market breakup by 4 Regions (North America, Europe, Asia Pacific and Rest of World)

All the major players have been covered from 3 Viewpoints (Overview, Recent Development, and Revenue Analysis) Illumina, Inc., Abbott Laboratories, Thermo Fisher Scientific, Inc, QIAGEN N.V. and Roche Holding AG

About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food & Beverages, Power & Energy, Information Technology, Telecom & Internet, Chemical, Logistics & Automotive, Consumer Goods & Retail, Building, and Construction, & Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more. Our research helps to make business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them with findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis, and forecasting that is essential in today's ultra-competitive markets.

Contact Us:

Renub Research

Phone No: +1 678-302-0700 (USA) | +91–120–421–9822 (IND)

Email: info@renub.com

Web: https://www.renub.com

Follow on Linkedin: https://www.linkedin.com/company/renub-research

Follow on Twitter: @renubresearch

[maxihealth]

GAO Report on MIPS

The Government Accountability Office (GAO) last week published a report evaluating the Merit-based Incentive Payment System (MIPS). MIPS is an approach for CMS to pay physicians caring for Medicare beneficiaries based not just on volume but on value. MIPS evaluates provider value along four dimensions: (1) quality, (2) improvement activities, (3) promoting interoperability, and (4) cost. Below I summarize the report including background on the MIPS program, the results of the GAO evaluation of MIPS scores and bonus payments, and summary of stakeholder feedback.

MIPS PROGRAM BACKGROUND

Exemptions. Some providers can be exempt from MIPS, typically if they have smaller practices. This is for two reasons: first the burden of MIPS reporting is more burdensome to small providers (due to economies of scale) and because smaller sample sizes mean that quality measures are less reliable. Physicians can be exempt from MIPS if they do not meet all of the following 3 criteria: (i) billed more than $90,000 for Part B services (ii) seen more than 200 Part B patients, and (iii) rendered more than 200 covered professional services to Part B patients.

Individuals vs. groups. Physicians can participate in MIPS either as individual physicians or as a group practice. The unit of observation for the group practice is the Tax Identification Number or TIN. Since 2018, individual physicians can also participate as “virtual groups” if they want to pool their scores, but operate as separate TINs. This increases the sample sizes and makes quality measures less volatile on a year-to-year basis.

Alternative Payment Models. Some physicians also participate in alternative payment models (APM) such as the Medicare Shared Savings Program (MSSP). Providers that are part of an APM entity may be collectively scored as an APM entity group and payment adjustments may occur based on the APM rules.

Performance Scores

Quality measures. Physicians are required to select at least 6 quality measures related to the care they provided to their patients during the year. Some quality measures are selected from pre-determined specialty list, but physicians get to choose the 6 measures over which they are evaluated.

Improvement activities. These are activities the practices must engage in to improve the practice. Examples include completing CDC’s antibiotic stewardship course.

Interoperability. This requirement relates to promiting patient engagement and insuring that electronic health records are certified and that the physicians systems are capable of e-prescribing.

Cost. Cost is calculated based on the total cost of care for all of the physician’s attributed patients based on Medicare Part A and B claims.

Bonus points. Providers can get bonus points if they have “complex” patients based on the share of patients who are dual eligible and there is a “small practice bonus” for practices with 15 or fewer providers who submit at least 1 quality measure.

Payments. Practices with higher scores get bonus payments and those with lower scores receive penalties. The payments are set in a budget neutral fashion so that (outside of the costs for CMS to administer the MIPS program) there is no net impact of these payments on the CMS budget. The maximum negative payment is -9%; the maximum positive payment is set to ensure that the program remains budget neutral in a given year. In 2021, the range was -9% to +9%.

RESULTS OF GAO MIPS ANALYSIS

How did Medicare physicians fare on the MIPS program? GAO writes:

… MIPS final scores were generally high from 2017 through 2019, with most MIPS-eligible providers qualifying for a positive payment adjustment. Across the 3 years, median final scores ranged from about 89.7 to 99.6 (out of a possible 100)—well above the performance threshold (see fig. 2).26 At least 93 percent of providers qualified for a positive payment adjustment in any year, and no more than 4.8 percent of providers qualified for a negative payment adjustment…

The maximum positive payment adjustment for any of performance years 2017 through 2019 resulted in relatively small increases in Medicare payments. For example, a provider with $90,000 in Medicare Physician Fee Schedule payments would only see an increase of $1,692 in payment year 2019 if they received the maximum positive adjustment of 1.88 percent based on their performance in 2017.

STAKEHOLDER FEEDBACK

Unsurprisingly, provider groups welcomed more flexibility. For instance, some provider groups received exemptions from reporting along certain dimensions (e.g., radiologists and pathologists did not have to report “promoting interoperability”). Smaller provider groups also appreciated the “small practice bonus” and the low volume threshold which exempted the smallest providers from MIPS participation.

Key critiques include: that feedback was not timely or meaningful to many providers.

Feedback is not timely. Providers have to submit prior year data by the end of March and then providers do not get feedback from the CMS analysis until July. From the provider perspective, this is already more than 6 months into the next year. From CMS’s perspective, speeding up the data submission deadlines is likely to receive pushback from providers about the undue burden of data submission.

Feedback is not meaningful. Practices are more interested in their performance relative to their peers in the same specialty and geographic areas and asked CMS to provide those statistics. Also, many providers–especially larger practices–may be choosing quality measures strategically to maximize their payments. A number of stakeholders also noted that the measures of interest were not very clinically meaningful. Many believe that MIPS leads to providers prioritizing reporting over quality of care, since it is (financially) better to choose metrics where the practice is already performing well rather than ones where the practice would need to improve.

Robustness of metrics. Some metrics do not happen frequently enough to be precisely measured. CMS faces the challenge that the more specific the measure is, the more relevant it will be to certain physicians; however, the more specific the measure becomes, the smaller sample size and less robust quality metric becomes.

ROI. Practice return on investment from MIPS participation was low. The payment bonuses were fairly low, but the administrative burden and cost to the practice was fairly high.

MIPS VALUE PATHWAY (MVP)

To address some challenges, CMS’s 2022 proposed rule plans to implement the MIPS Value Pathway (MVP) in performance year 2023.

If the rule is finalized as proposed, MVPs will allow providers the option of reporting on a group of activities and measures from the four MIPS performance categories that are relevant to a specific specialty, medical condition, or episode of care.39 Under the proposal, in 2023, providers may register to report data and receive feedback on one of seven MVPs related to the following clinical topics: (1) anesthesia, (2) chronic disease management, (3) emergency medicine, (4) heart disease, (5) lower extremity joint repair, (6) rheumatology, and (7) stroke

In addition, CMS proposes to allow subgroup reporting for MVPs..[which] would allow a specialty within a large multi-specialty group to register as a subgroup and receive more clinically meaningful feedback on its measures and activities in the quality, improvement activities, and cost performance categories.

The MVP framework would also standardize performance measurement across selected specialties, medical conditions, or episodes of care. A more cohesive set of measures can help reduce the amount of “gaming” the system that providers can do.

GAO Report on MIPS posted first on https://carilloncitydental.blogspot.com

[happilysassycheesecake-blog]

Microprocessor and GPU Market worth 83.69 Billion USD by 2022

"Microprocessor and GPU Market by Application (Consumer Electronics, Server, Automotive, BFSI, Industrial), Architecture (X86, ARM, MIPS, Power), GPU by Type (Discrete, Integrated), and Geography - Global Forecast to 2022", this market is expected to be valued at USD 83.69 Billion by 2022, at a CAGR of 2.2% between 2017 and 2022. The major factors driving the growth of the microprocessor and GPU market include the growing demand for wearable devices such as smartwatches, migration of data from on-premise environments to cloud-based server environments driving the growth for server processors, and growing impact of Internet of Things (IoT).

https://www.marketsandmarkets.com/Market-Reports/micro-processors-market-28633568.html

[qppmips]

A Guide for QPP MIPS Consultants to Maximize Payment Adjustments

QPP MIPS consultants play a crucial role in helping eligible clinicians navigate the QPP MIPS program and achieve the highest possible score. Read more about how to maximize performance. The Quality Payment Program (QPP) MIPS is a performance-based payment system that measures eligible clinicians' performance in four categories: Quality, Improvement Activities, Promoting Interoperability, and Cost. For QPP MIPS consultants, understanding the QPP MIPS program's ins and outs is crucial for ensuring their clients receive the highest possible payment adjustment, especially with the introduction of QPP MIPS 2022.

Read more:https://qppmips.blogspot.com/2023/03/a-guide-for-qpp-mips-consultants-to.html

Phone number: (888) 902-1035

Address: Ontario, California, Ontario, CA 91761, USA

Website:https://qppmips.com/

[somya08]

Digital Signal Processor (DSP) Market Research Report 2021

The research team projects that the Digital Signal Processor (DSP) market size will grow from XXX in 2020 to XXX by 2027, at an estimated CAGR of XX. The base year considered for the study is 2020, and the market size is projected from 2020 to 2027.

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 50 major countries. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-digital-signal-processor-2021-424

By Market Players:

Altera Corporation

Analog Devices

Texas Instruments

Broadcom Corporation

Freescale Semiconductor

STMicroelectronics

Infineon Technologies

NXP Semiconductors

Renesas Electronics

LSI Corporation

Crestron

Ceva

Marvell Technology Group

MIPS Technologies

Qualcomm

Samsung Electronics

Toshiba

Xilinx Incorporated

By Type

Single-core DSP

Multi-core DSP

By Application

Consumer Electronics

Automotive

Industrial

Military,Defense & Aerospace

Medical

Others

By Regions/Countries:

North America

United States

Canada

Mexico

East Asia

China

Japan

South Korea

Europe

Germany

United Kingdom

France

Italy

Russia

Spain

Netherlands

Switzerland

Poland

South Asia

India

Pakistan

Bangladesh

Southeast Asia

Indonesia

Thailand

Singapore

Malaysia

Philippines

Vietnam

Myanmar

Middle East

Turkey

Saudi Arabia

Iran

United Arab Emirates

Israel

Iraq

Qatar

Kuwait

Oman

Africa

Nigeria

South Africa

Egypt

Algeria

Morocoo

Oceania

Australia

New Zealand

South America

Brazil

Argentina

Colombia

Chile

Venezuela

Peru

Puerto Rico

Ecuador

Rest of the World

Kazakhstan

Points Covered in The Report

The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years data history and forecast.

The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.

Data and information by market player, by region, by type, by application and etc, and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to Purchase

To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and its impact in the global market.

Learn about the market strategies that are being adopted by leading respective organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

The report focuses on Global, Top 10 Regions and Top 50 Countries Market Size of Digital Signal Processor (DSP) 2016-2021, and development forecast 2022-2027 including industries, major players/suppliers worldwide and market share by regions, with company and product introduction, position in the market including their market status and development trend by types and applications which will provide its price and profit status, and marketing status & market growth drivers and challenges, with base year as 2020.

Key Indicators Analysed

Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2021 & Sales by Product Types.

Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2022-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its production, consumption, import & export, sales volume & revenue forecast.

Market Analysis by Product Type: The report covers majority Product Types in the Digital Signal Processor (DSP) Industry, including its product specifcations by each key player, volume, sales by Volume and Value (M USD).

Markat Analysis by Application Type: Based on the Digital Signal Processor (DSP) Industry and its applications, the market is further sub-segmented into several major Application of its industry. It provides you with the market size, CAGR & forecast by each industry applications.

Market Trends: Market key trends which include Increased Competition and Continuous Innovations.

Opportunities and Drivers: Identifying the Growing Demands and New Technology

Porters Five Force Analysis: The report will provide with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

COVID-19 Impact

Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Digital Signal Processor (DSP) market in 2021. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Get the Complete Report & TOC @ https://www.grandresearchstore.com/semiconductor-and-electronics/global-digital-signal-processor-2021-424

Table of content

1 Report Overview

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Digital Signal Processor (DSP) Revenue

1.4 Market Analysis by Type

1.4.1 Global Digital Signal Processor (DSP) Market Size Growth Rate by Type: 2021 VS 2027

1.4.2 Single-core DSP

1.4.3 Multi-core DSP

1.5 Market by Application

1.5.1 Global Digital Signal Processor (DSP) Market Share by Application: 2022-2027

1.5.2 Consumer Electronics

1.5.3 Automotive

1.5.4 Industrial

1.5.5 Military,Defense & Aerospace

1.5.6 Medical

1.5.7 Others

1.6 Study Objectives

1.7 Years Considered

1.8 Overview of Global Digital Signal Processor (DSP) Market

1.8.1 Global Digital Signal Processor (DSP) Market Status and Outlook (2016-2027)

1.8.2 North America

1.8.3 East Asia

1.8.4 Europe

1.8.5 South Asia

1.8.6 Southeast Asia

1.8.7 Middle East

1.8.8 Africa

1.8.9 Oceania

1.8.10 South America

1.8.11 Rest of the World

2 Market Competition by Manufacturers

2.1 Global Digital Signal Processor (DSP) Production Capacity Market Share by Manufacturers (2016-2021)

2.2 Global Digital Signal Processor (DSP) Revenue Market Share by Manufacturers (2016-2021)

2.3 Global Digital Signal Processor (DSP) Average Price by Manufacturers (2016-2021)

2.4 Manufacturers Digital Signal Processor (DSP) Production Sites, Area Served, Product Type

3 Sales by Region

3.1 Global Digital Signal Processor (DSP)

CONTACT US: 276 5th Avenue, New York , NY 10001,United States International: (+1) 646 781 7170 / +91 8087042414 Email: help@grandresearchstore.com

Follow Us On linkedin :- https://www.linkedin.com/company/grand-research-store/

[andy1199posts]

Microprocessor and GPU Market Expected to reach 83.69 Billion USD by 2022

Microprocessor and GPU Market Expected to reach 83.69 Billion USD by 2022

According to the new market research report on “Microprocessor and GPU Market by Application (Consumer Electronics, Server, Automotive, BFSI, Industrial), Architecture (X86, ARM, MIPS, Power), GPU by Type (Discrete, Integrated), and Geography – Global Forecast to 2022″, this market is expected to be valued at USD 83.69 Billion by 2022, at a CAGR of 2.2% between 2017 and 2022. The major factors…

[hudsonespie]

OOCL To Sell 100% Of Long Beach Container Terminal For US$ 1.78 Billion

Orient Overseas (International) Limited and Macquarie Infrastructure Partners (“MIP”) announced that OOIL’s wholly-owned subsidiaries, OOCL LLC and Long Beach Container Terminal, Inc., have entered into a Sale and Purchase Agreement to sell 100% of LBCT LLC to a consortium led by MIP, for US$1.78 billion. LBCT LLC operates the Long Beach Container Terminal (“LBCT”) in the Port of Long Beach, California, United States.

The sale is undertaken pursuant to the National Security Agreement entered into by OOIL, Faulkner Global Holdings Limited, a subsidiary of COSCO SHIPPING Holdings Co., Ltd, and the U.S. Department of Homeland Security and the U.S. Department of Justice on July 6, 2018, under which OOIL committed to divest its ownership of the Long Beach Container Terminal business.

As part of the sale, Orient Overseas Container Line Limited (“OOCL”), a subsidiary of OOIL, will also enter into a Container Stevedoring and Terminal Services Agreement with LBCT LLC for a 20-year period, confirming its significant long-term commitment to LBCT.

Representation Image – Credits: eurogate.de

Commenting on the sale, Andy Tung, Co-Chief Executive Officer of OOCL, said: “Over the past thirty years, we have developed Long Beach Container Terminal into the safest, most efficient and lowest-emission terminal in the United States. We are confident of the future prospects of the terminal under the ownership of MIP and its co-investors, and we look forward to being a long term strategic customer of Long Beach Container Terminal and the Port of Long Beach.”

Karl Kuchel, Chief Executive Officer of MIP, commented that: “We are pleased to acquire LBCT, a premier terminal in the largest port complex in North America, which serves as a gateway for trans-Pacific trade. This transaction marks another key milestone in our relationship with OOIL and we greatly appreciate their significant long-term customer commitment to LBCT. We look forward to partnering with the Port of Long Beach and the LBCT management team to ensure that LBCT delivers high-quality service to OOCL and our other customers going forward. We are also committed to completing the current expansion of LBCT by 2022, which will significantly increase the capacity of the terminal.”

The completion of the sale will be subject to approvals from the relevant regulatory authorities and other customary conditions.

J.P. Morgan is the financial adviser and Slaughter and May is the legal counsel to OOIL.

Reference: ooilgroup.com

Report an Error

from Storage Containers https://www.marineinsight.com/shipping-news/oocl-to-sell-100-of-long-beach-container-terminal-for-us-1-78-billion/ via http://www.rssmix.com/

[sunilkjadhav-blog]

Microprocessor and GPU Market by Application (Consumer Electronics, Server, Automotive, BFSI, Industrial), Architecture (X86, ARM, MIPS, Power), GPU by Type (Discrete, Integrated), and Geography

[keithsilviaus]

Understanding How MACRA and MIPS Make Documentation Matter Even More

Discover why your success in this QPP track depends on documenting.

You probably don’t need to be told Medicare physician reimbursement is currently seeing, as Modern Healthcare put it, “its biggest change since its launch in 1965.” To avoid financial penalty, approximately 622,000 U.S. clinicians (as estimated in CMS’ final rule about the program) must now participate in the Quality Payment Program CMS established to implement MACRA, the Medicare Access and Children’s Health Insurance Program (CHIP) Reauthorization Act of 2015.

What you might need is help understanding how MACRA, MIPS, APMs, bundled payments and other efforts to “drive the [U.S.] health care system towards greater value-based purchasing” affect your practice. As the U.S. healthcare system’s shift away from fee-for-service reimbursement gathers speed, it’s only natural providers have concerns and questions, MACRA is particularly far-reaching and complex. “Meaningful use is first-grade arithmetic,” Healthcare IT consultant Dan Golder told Modern Healthcare, referring to a familiar EHR incentive program MACRA is sunsetting, “and MIPS and MACRA are college-level calculus… The complexity of MIPS is going to be very difficult for physicians to stomach.”

MDCodePro specializes in helping practitioners increase their coding accuracy, regulatory compliance, and profitability. As we noted in our discussion of new U.S. tax law, we don’t presume to present expert legal or financial advice. But while we can’t offer a comprehensive review of MACRA’s many provisions (the final ruling runs 1,653 pages, Healthcare Informatics reports,) we can help you refresh your understanding of MACRA’s basics and point out some of its impact on how you document the services you provide your patients, because documentation is always key in optimal coding.

A Summary of MACRA MIPS and APMs

MACRA uses a two-track Quality Payment Program (QPP) to reward practitioners for quality care delivered to Medicare beneficiaries:

The Merit-Based Incentive Payment System (MIPS) consolidates current pay-for-performance programs and determines payment bonuses, penalties, and adjustments based on providers’ scores in four categories: quality, resource use, clinical practice improvement activities, and meaningful use of certified EHRs. Providers have the flexibility of choosing the MACRA MIPS quality measures most appropriate to their practices.

Advanced Alternative Payment Models (APMs) incentivize high-quality, cost-effective care by exempting qualifying participants from MIPS reporting requirements and payment adjustments.

The existence of “MIPS APMs” complicates the QPP’s two-track structure somewhat; however, according to CMS, “[m]ost Advanced APMs are also MIPS APMs.” Most clinicians will participate in the MIPS track. Clinicians or groups serving 200 or fewer Medicare Part B beneficiaries or who have billed $90,000 or less to Medicare are exempt.  

Checking your participation status is vital. (You can do so here.) Penalties for eligible practitioners who aren’t participating will reach as much as 9% by 2022, while participant rewards will climb equally as high.

Why MIPS Demands You Increase Attention to Documentation

MACRA will impact medical coding in a very practical way because, in some cases, it necessitates new codes. For example, because the law aims to improve coordination of care among providers across specialties and settings, it requires CMS develop new codes for identifying episodes of care and patient condition groups, plus group classification codes.

But any understanding of MACRA and MIPS that doesn’t consider the law’s implications for documentation, so foundational to sound coding, would be incomplete. “It’s important to remember,” write Kathryn DeVault and colleagues for AHIMA, “that accurate documentation and complete and compliant coding impacts almost all areas of quality reporting and, ultimately, provider reimbursement.”

Writing for the AAPC, billing and coding expert and instructor Rhonda Buckholtz makes MIPS’ stakes clear: “MIPS starts in 2019 with 4 percent on the line…That could add up to over $200,000 for even smallish practices. Who couldn’t use that much extra revenue in their practice? Which one of us can afford to lose that much?”

Dedicate Yourself to Improved Documentation with MDCodePro

As part of your adjustment to MACRA, then, decide to make your medical coding as strong as possible with MDCodePro.

Our methodology, which has been validated in repeated audits, equips you to document each patient visit to support its optimal CPT® code. Our short series of video lectures streamline CMS’ complicated coding regulations into a manageable and memorable system you can put into practice right away. And our easy-to-use code generator uses the data you give it to identify the code ensuring your greatest accuracy, regulatory compliance, and legitimate reimbursement.

Don’t let weak documentation keep you from full compliance with MACRA or the revenue to which you’re entitled under the new law. Sign up for MDCodePro today.

The post Understanding How MACRA and MIPS Make Documentation Matter Even More appeared first on MDCodePro.

from MDCodePro https://mdcodepro.com/blog/understanding-macra-mips/ from MDCodePro https://mdcodepro.tumblr.com/post/175934503562

[mdcodepro]

Understanding How MACRA and MIPS Make Documentation Matter Even More

Discover why your success in this QPP track depends on documenting.

You probably don’t need to be told Medicare physician reimbursement is currently seeing, as Modern Healthcare put it, “its biggest change since its launch in 1965.” To avoid financial penalty, approximately 622,000 U.S. clinicians (as estimated in CMS’ final rule about the program) must now participate in the Quality Payment Program CMS established to implement MACRA, the Medicare Access and Children’s Health Insurance Program (CHIP) Reauthorization Act of 2015.

What you might need is help understanding how MACRA, MIPS, APMs, bundled payments and other efforts to “drive the [U.S.] health care system towards greater value-based purchasing” affect your practice. As the U.S. healthcare system’s shift away from fee-for-service reimbursement gathers speed, it’s only natural providers have concerns and questions, MACRA is particularly far-reaching and complex. “Meaningful use is first-grade arithmetic,” Healthcare IT consultant Dan Golder told Modern Healthcare, referring to a familiar EHR incentive program MACRA is sunsetting, “and MIPS and MACRA are college-level calculus… The complexity of MIPS is going to be very difficult for physicians to stomach.”

MDCodePro specializes in helping practitioners increase their coding accuracy, regulatory compliance, and profitability. As we noted in our discussion of new U.S. tax law, we don’t presume to present expert legal or financial advice. But while we can’t offer a comprehensive review of MACRA’s many provisions (the final ruling runs 1,653 pages, Healthcare Informatics reports,) we can help you refresh your understanding of MACRA’s basics and point out some of its impact on how you document the services you provide your patients, because documentation is always key in optimal coding.

A Summary of MACRA MIPS and APMs

MACRA uses a two-track Quality Payment Program (QPP) to reward practitioners for quality care delivered to Medicare beneficiaries:

The Merit-Based Incentive Payment System (MIPS) consolidates current pay-for-performance programs and determines payment bonuses, penalties, and adjustments based on providers’ scores in four categories: quality, resource use, clinical practice improvement activities, and meaningful use of certified EHRs. Providers have the flexibility of choosing the MACRA MIPS quality measures most appropriate to their practices.

Advanced Alternative Payment Models (APMs) incentivize high-quality, cost-effective care by exempting qualifying participants from MIPS reporting requirements and payment adjustments.

The existence of “MIPS APMs” complicates the QPP’s two-track structure somewhat; however, according to CMS, “[m]ost Advanced APMs are also MIPS APMs.” Most clinicians will participate in the MIPS track. Clinicians or groups serving 200 or fewer Medicare Part B beneficiaries or who have billed $90,000 or less to Medicare are exempt.  

Checking your participation status is vital. (You can do so here.) Penalties for eligible practitioners who aren’t participating will reach as much as 9% by 2022, while participant rewards will climb equally as high.

Why MIPS Demands You Increase Attention to Documentation

MACRA will impact medical coding in a very practical way because, in some cases, it necessitates new codes. For example, because the law aims to improve coordination of care among providers across specialties and settings, it requires CMS develop new codes for identifying episodes of care and patient condition groups, plus group classification codes.

But any understanding of MACRA and MIPS that doesn’t consider the law’s implications for documentation, so foundational to sound coding, would be incomplete. “It’s important to remember,” write Kathryn DeVault and colleagues for AHIMA, “that accurate documentation and complete and compliant coding impacts almost all areas of quality reporting and, ultimately, provider reimbursement.”

Writing for the AAPC, billing and coding expert and instructor Rhonda Buckholtz makes MIPS’ stakes clear: “MIPS starts in 2019 with 4 percent on the line…That could add up to over $200,000 for even smallish practices. Who couldn’t use that much extra revenue in their practice? Which one of us can afford to lose that much?”

Dedicate Yourself to Improved Documentation with MDCodePro

As part of your adjustment to MACRA, then, decide to make your medical coding as strong as possible with MDCodePro.

Our methodology, which has been validated in repeated audits, equips you to document each patient visit to support its optimal CPT® code. Our short series of video lectures streamline CMS’ complicated coding regulations into a manageable and memorable system you can put into practice right away. And our easy-to-use code generator uses the data you give it to identify the code ensuring your greatest accuracy, regulatory compliance, and legitimate reimbursement.

Don’t let weak documentation keep you from full compliance with MACRA or the revenue to which you’re entitled under the new law. Sign up for MDCodePro today.

The post Understanding How MACRA and MIPS Make Documentation Matter Even More appeared first on MDCodePro.

from MDCodePro https://mdcodepro.com/blog/understanding-macra-mips/